A candesartan cilexetil/hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapy
M. Campbell et al., A candesartan cilexetil/hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapy, CLIN EXP HY, 23(4), 2001, pp. 345-355
In this double-blind, placebo-controlled, randomised, parallel-group study,
a combination tablet of candesartan cilexetil/hydrochlorothiazide (HCTZ),
16/12.5 mg once daily, reduced sitting diastolic blood pressure (DBP) signi
ficantly more (p = 0.037) than candesartan cilexetil/placebo, 16 mg once da
ily, in patients with mild to moderate primary hypertension (n = 328) who h
ad not reached target blood pressure with candesartan cilexetil, 16 mg once
daily. Ar the end of the 8-week double-blind treatment period, the adjuste
d mean reductions in sitting DBP, 24 h post dose, were 7.5 mm Hg in the can
desartan cilexetil/HCTZ treatment group and 5.5 mm Hg in the candesartan ci
lexetil/placebo treatment group, corresponding to an adjusted mean differen
ce between treatments of 2.0 mm Hg in favour of candesartan cilexetil/HCTZ
(95% CI 0.1-3.8 mm Hg, p = 0.037). The adjusted mean reductions in sitting
systolic blood pressure, 24 h post dose, were 12.0 mm Hg and 7.5 mm Hg, res
pectively, corresponding to an adjusted mean difference between treatments
of 4.5 mm Hg (95% CI 1.1-8.0, p = 0.01). Consistent with the placebo-like t
olerability of candesartan cilexetil reported in other studies, both treatm
ents were very well tolerated, with a similar pattern and low frequency of
adverse events in both treatment groups.